TRAVERE THERAPEUTICS, INC. Share-based Payment Arrangement, Accelerated Cost
TRAVERE THERAPEUTICS, INC. (TVTX) reported Share-based Payment Arrangement, Accelerated Cost of $362.13 thousand for the 3-month period ending 2013-09-30, per its 10-Q/A filed 2015-07-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost · last filed 2015-07-09
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2013-09-30 was $362.13K, a 83.89% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2013-06-30 was $70.87K, a 97.32% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2013-03-31 was $138.37K, a 86.21% decline year-over-year.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for the quarter ending 2012-12-31 was $107.12K.
- TRAVERE THERAPEUTICS, INC. share-based payment arrangement, accelerated cost for fiscal 2012 was $6.40M.
| Period end | Share-based Payment Arrangement, Accelerated Cost 3 month | Share-based Payment Arrangement, Accelerated Cost 3 month as first filed | Share-based Payment Arrangement, Accelerated Cost 6 month | Share-based Payment Arrangement, Accelerated Cost 9 month | Share-based Payment Arrangement, Accelerated Cost 9 month as first filed | Share-based Payment Arrangement, Accelerated Cost 10 month | Share-based Payment Arrangement, Accelerated Cost 12 month | Share-based Payment Arrangement, Accelerated Cost 22 month | Share-based Payment Arrangement, Accelerated Cost 25 month | Share-based Payment Arrangement, Accelerated Cost 28 month | Share-based Payment Arrangement, Accelerated Cost 31 month |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2013-09-30 | $362.13K 10-Q/A · filed 2015-07-09 | $1.64M 10-Q · filed 2013-11-13 | $433.00K derived: sum of 2 quarters · filed 2015-07-09 | $571.37K 10-Q/A · filed 2015-07-09 | $1.85M 10-Q · filed 2013-11-13 | $678.49K derived: sum of 4 quarters · filed 2015-07-09 | $8.50M 10-Q/A · filed 2015-07-09 | ||||
| 2013-06-30 | $70.87K 10-Q · filed 2013-09-16 | $209.24K 10-Q · filed 2013-09-16 | $316.36K derived: sum of 3 quarters · filed 2013-09-16 | $2.56M derived: sum of 4 quarters · filed 2015-07-09 | $6.86M 10-Q · filed 2013-09-16 | ||||||
| 2013-03-31 | $138.37K 10-Q/A · filed 2013-09-16 | $245.49K derived: sum of 2 quarters · filed 2013-09-16 | $2.49M derived: sum of 3 quarters · filed 2015-07-09 | $5.14M derived: sum of 4 quarters · filed 2015-07-09 | $6.79M 10-Q/A · filed 2013-09-16 | ||||||
| 2012-12-31 | $107.12K derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2013-09-16 | $2.35M derived: sum of 2 quarters · filed 2015-07-09 | $5.00M derived: sum of 3 quarters · filed 2015-07-09 | $6.40M 10-K/A · filed 2013-09-16 | $6.65M 10-K/A · filed 2013-09-16 | ||||||
| 2012-09-30 | $2.25M 10-Q/A · filed 2015-07-09 | $4.89M derived: sum of 2 quarters · filed 2015-07-09 | $6.29M 10-Q/A · filed 2015-07-09 | ||||||||
| 2012-06-30 | $2.65M 10-Q · filed 2013-09-16 | $3.65M 10-Q · filed 2013-09-16 | |||||||||
| 2012-03-31 | $1.00M 10-Q/A · filed 2013-09-16 | ||||||||||
| 2011-12-31 | $254.33K 10-K/A · filed 2013-09-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |